UPPDATERING Hematology / Oncology 2024
ESMO-kongressen 2023
Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer that is taxane-naive. Amivantamab combinations therapies are emerging as new options for EGFR mutated advanced NSCLC. Antibody-drug combinations improve outcomes for patients who have metastatic or inoperable breast cancer. Digital health technologies are revolutionising cancer care.
Du använder en äldre version av din webbläsare, så vissa funktioner kanske inte visas korrekt.
MINIMALkrav: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15-18, Apple Safari 7, SeaMonkey 2.15-2.23.
Meeting Resources19 Oct 2023OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.Access to resources.
OncologyPRO erbjuder nu mötesresurser: +3.000 XNUMX bilder och webbsändningar; abstrakt och eposters.
Daily ReporterDatopotamab deruxtecan reached the PFS endpoint for previously treated NSCLC23 Oct 2023TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
Daily Reporter177Lu PSMA-617 förbättrar rPFS för metastaserande kastrationsresistenta prostatacancerpatienter som är taxan-naiva 23 okt 2023 PSMAfore-studiens resultat begränsas av det faktum att de inte visar någon fördel i termer av OS.
Registrera dig för biljetter eller bås
Karta över lokaler och hotell i närheten
Munich - Holiday Inn Munich - Centrum, Bayern, Tyskland Munich - Holiday Inn Munich - Centrum, Bayern, Tyskland
Prenumerera